ANTIVIRAL IMMUNO-MODULATION

Immunotherapy is 21st century medicine.    Divina Biotech harnesses the innate immune response to mitigate viral load & increase adaptive immunity.   Divina Biotech enters Phase 1 clinical trials Q3-Q4 2020.   

ONCOLOGY 

Oncolytic viral therapy is re-emerging to the forefront of cancer therapy.  The first oncolytic viral therapy was approved by the FDA in 2016.  Divina Biotech's  oncolytic virus will be entering Phase 1  Clinical Trials Q1 2021.